Study of GT-02287 for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 85 years old
- You have been diagnosed with Parkinson's disease within the last 5 years and it is mild to moderate (Hoehn & Yahr stage 1 to 2.5)
- You are either not taking any Parkinson's medications yet, or you have been on a stable dose of your current Parkinson's drugs for at least 3 months
- You do not have a genetic mutation (other than a specific type called GBA1) known to cause Parkinson's
- You are willing to undergo genetic testing and a spinal tap (lumbar puncture) to check for a protein marker (alpha-synuclein seeding)
- You do not have other serious health problems like dementia, hallucinations, or conditions that make a spinal tap unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.